Rolf Billeskov, Post doc

Rolf Billeskov
Statens Serum Institut
Artillerivej 5 , 81/348
2300 København S
3268 3268


  • Pre-clinical development and testing of new vaccines and vaccine strategies against tuberculosis


  • Analysis of immune response during different stages of experimental Mycobacterium tuberculosis infection in mice
  • Optimize strategies to improve post-exposure vaccine induced protection against tuberculosis with regards to administration route, timing of immunizations, antigen dose

Udvalgte publikationer

  • Billeskov R, Wang Y, Solaymani-Mohammadi S, Frey B, Kulkarni S, Andersen P, Agger EM, Sui Y, Berzofsky JA Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces DC4 T Cells with Enhanced Functional Avidity and Protective Efficacy. J Immunol.2017; 198(9), 3494-3506 PubMed
  • Sui Y, Frey B, Wang Y, Billeskov R, Kulkarni S, McKinnon K, Rouke T, Fritts L, Miller CJ, Berzofsky JA Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques. PLoS Pathog.2017; 13(5), PubMed
  • Solaymani-Mohammadi S, Lakhdari O, Minev I, Shenouda S, Frey BF, Billeskov R, Singer SM, Berzofsky JA, Eckmann L, Kagnoff MF Lack of the programmed death-1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules. J Leukoc Biol.2016; 99(3), 475-482 PubMed
  • Knudsen NPH, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN, Fox CB, Meinke A, D Oro U, Casini D, Bonci A, Billeskov R, De Gregorio E, Rappuoli R, Harandi AM, Andersen P, Agger EM Different human vaccine adjuvants promote distinct antigen-independant immunological signatures tailored to different pathogens. Sci Rep.2016; 6, 19570 PubMed
  • Billeskov R, Tan EV, Cang M, Abalos RM, Burgos J, Pedersen BV, Christensen D, Agger EM, Andersen P Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis. PLoS One.2016; 11(8), e0161217 PubMed